antidepressants and semaglutide Computational phenotyping of effort-based decision-making in type-2 diabetes on off SSRIs and weight gain. Here's

De Barra C, Khalil M, Mat A, ODonnell C, Shaamile F, Brennan K, et al

Advantage : Semaglutide Summary and Verdict# Ecnoglutide's biased GLP-1 signaling represents a scientifically novel approach, and SLIMMER Phase 3 data (15.4% weight loss at 48 weeks) are comparable to semaglutide's STEP 1 results (14.9% at 68 weeks)

A subgroup analysis by weight reduction iced the case for proportionate benefit of symptom relief and less inflammation (by biomarkers) as a function of weight loss These are striking results for people with HFpEf given the only other drugs that have thus far shown benefit are the sodium-glucose cotransporter 2 (SGLT2) inhibitors

However, most insurance plans do not cover GLP-1 medications for weight loss as they consider obesity and overweight a cosmetic concern rather than a medical need

No medications that affect b12 absorption